<DOC>
	<DOCNO>NCT02797587</DOCNO>
	<brief_summary>This study randomize control trial ( RCT ) compare effect varenicline , cytisine , nicotine replacement therapy ( NRT ) reduce : 1 ) alcohol use craving , 2 ) smoking ; 3 ) inflammation risk coronary heart disease ( CHD ) mortality among 400 HIV-infected Russians , heavy alcohol consumption tobacco use .</brief_summary>
	<brief_title>Studying Partial-agonists Ethanol Tobacco Elimination Russians With HIV ( St PETER HIV )</brief_title>
	<detailed_description>HIV-infected heavy drinking smoker high risk coronary heart disease ( CHD ) death . The mechanisms driving increase CHD risk HIV-infected people unclear , link inflammation . HIV , heavy drinking , smoke pro-inflammatory . HIV viral suppression antiretroviral therapy eliminate elevate CHD risk increase inflammation ( i.e. , pre-HIV infection level restore ) . Interventions reduce alcohol use , smoking , HIV-infected people could lower inflammation , CHD death risk . Varenicline cytisine proven therapy smoke cessation . When compare placebo , varenicline high cessation rate cytisine . Human trial suggest varenicline also efficacy reduce alcohol consumption crave heavy drinking smoker . In murine model , cytisine reduces alcohol consumption . The comparative efficacy varenicline cytisine reduce alcohol consumption extension , inflammation , CHD , mortality risk , human test , comparative effectiveness test smoking . Neither drug test smoke cessation nicotine replacement therapy ( NRT ) HIV-infected heavy drinking smoker . Three compel reason test varenicline cytisine HIV-infected heavy drinking smoker : 1 ) show promise HIV-uninfected people ; 2 ) morbidity cause heavy drinking smoke HIV-infected person significant ; 3 ) treat heavy drinking smoke one medication represent significant advance reduce polypharmacy improve patient care . Thus , investigator propose 4-arm placebo-controlled randomize control trial ( RCT ) among 400 HIV-infected heavy drinking smoker . Trial arm varenicline+NRT placebo , cytisine+NRT placebo , NRT+varenicline placebo , NRT+cytisine placebo . All participant receive counseling ( alcohol &amp; tobacco ) medication ( placebo &amp; active ) . Specific aim compare effect varenicline , cytisine , NRT 3 month past month % heavy drinking day alcohol craving , cigarette per day smoking abstinence ( verified carbon monoxide ) , inflammation ( hsCRP , IL-6 ) , CHD ( Reynolds risk score ) , mortality ( VACS index ) risk . Investigators hypothesize ( 1 ) Varenicline great efficacy NRT reduce heavy drinking , smoking , inflammation , CHD mortality risk ; ( 2 ) Cytisine great efficacy NRT ; ( 3 ) Varenicline great efficacy cytisine outcome . Investigators conduct RCT , Studying Partial-agonists Ethanol Tobacco Elimination Russians HIV ( St PETER HIV ) , country HIV epidemic high per-capita alcohol consumption smoking . Investigators recruit ongoing Russia ARCH cohort St. Petersburg ( part NIAAA fund HIV/AIDS Alcohol Consortium - URBAN ARCH ) . If investigator hypothesis correct , St PETER HIV could make nicotinic partial-agonists standard care HIV+ heavy drinking smoker , lead reduce inflammation , CHD mortality risk `` one drug , two disease '' approach . This trial address paucity RCT data guide treatment CHD risk factor HIV-infected people . The Russia ARCH Cohort St PETER HIV study draw establish cohort HIV-infected smoker heavy drinker compare effect two partial nicotinic receptor , varenicline cytisine , alcohol consumption , alcohol craving , smoking , inflammation , CHD risk mortality risk . St PETER HIV address paucity randomize control trial data guide treatment heavy alcohol consumption smoke HIV-infected people .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>1870 year old HIVinfected â‰¥ 5 heavy drinking day past 30 day ( NIAAA atrisk drinking level ) Smoking average least 5 cigarette per day Provision contact information 2 contact assist followup Stable address within 100 kilometer Possession telephone ( home cell ) Interest cut down/quitting alcohol tobacco Able willing comply study protocol procedures Not fluent Russian Cognitive impairment Pregnant planning become pregnant next 3 month Breastfeeding Unstable psychiatric illness ( i.e . , answer yes follow : past three month ) active hallucination ; b ) mental health symptom prompt visit ED hospital ; mental health medication change due worsen symptom ; presence suicidal ideation ) History pheochromocytoma Taking smoke cessation medication past 30 day History seizures History Buerger 's disease Acute coronary syndrome within 1 month enrollment Systolic BP &gt; 180 mm Hg diastolic BP &gt; 105 mm Hg Currently take antituberculosis medication Currently take Galantamine Physostigmine BAC level 0.10 % high Known allergy varenicline ( Chantix ) cytisine ( Tabex )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alcohol Use</keyword>
	<keyword>Tobacco Use</keyword>
	<keyword>Smoking</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Coronary Heart Disease</keyword>
	<keyword>Russia</keyword>
	<keyword>Varenicline</keyword>
	<keyword>Cytisine</keyword>
	<keyword>Nicotine Replacement Therapy</keyword>
	<keyword>Partial Agonist Therapy</keyword>
	<keyword>HIV</keyword>
	<keyword>Reynolds risk score</keyword>
	<keyword>VACS index</keyword>
</DOC>